ArticleOncotarget2015
Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
Yue Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this paperpooled itcites it